Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financi...(217665 200497 Accumulated ot...),Health

Accumulated other comprehensive income - 3

Deficit accumulated during the

development stage (191,141) (155,894)

Total stockholders' equity 26,558 44,635

Total liabilities and stockholders' equity $60,044 $72,289

FAVRILLE, INC.

(a development stage company)

STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

Unaudited

Three Months ended Nine Months ended

September 30, September 30,

2007 2006 2007 2006

Operating expenses:

Research and

development $9,480 $7,487 $27,100 $23,370

General and

administrative 2,938 2,605 8,798 8,226

Total operating

expenses 12,418 10,092 35,898 31,596

Interest income 361 773 1,423 2,004

Interest expense (271) (266) (772) (644)

Other expense - - - (29)

Total other income, net 90 507 651 1,331

Net loss applicable to

common stockholders $(12,328) $(9,585) $(35,247) $(30,265)

Historical net loss

per share:

Basic and diluted $(0.37) $(0.33) $(1.10) $(1.13)

Weighted-average

shares - basic and

diluted 32,928,733 28,805,214 32,038,726 26,679,507

FAVRILLE, INC.

(a development stage company)

'/>"/>